Streetbeat News

Price Targets

MRK

Merck & Co (NYSE:MRK) has received mixed analyst ratings over the past quarter, with 9 analysts offering opinions ranging from bullish to indifferent. The average 12-month price target for MRK is $130.56, reflecting an 8.8% increase from the previous target of $120.00. Analysts from firms including Cantor Fitzgerald, TD Cowen, Deutsche Bank, Morgan Stanley, and BMO Capital have provided ratings and adjusted price targets, with the highest target being $135.00 and the lowest at $115.00. Merck's financial performance shows strong market presence, revenue growth, and financial health, with a market capitalization above industry average, a positive revenue trend, high net margin, ROE, and ROA, and a healthy debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 3:01 pm

AEO

Analysts have updated their ratings and price targets for American Eagle Outfitters (NYSE:AEO), with an average 12-month price target of $18.57, up from $15.70. The company has shown positive revenue growth, a high net margin, and strong ROE and ROA, with a lower than average debt-to-equity ratio. The majority of analysts are currently indifferent, with one somewhat bearish, reflecting a cautious outlook.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 3:01 pm

APLS

Apellis Pharmaceuticals (NASDAQ:APLS) has received 12 analyst ratings in the last three months, with a mix of bullish and bearish sentiments. The average 12-month price target is $67.67, down from the previous $69.40. Analysts from firms like Goldman Sachs, Citigroup, and others have adjusted their price targets and ratings, reflecting their latest views on the company's performance. Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company with a focus on the complement system. Despite a significant revenue growth rate of 400.54% as of September 30, 2023, the company's net margin and ROE are below industry averages, and it has a prudent debt-to-equity ratio of 0.47.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 3:00 pm

JXN

Four analysts have maintained a neutral stance on Jackson Financial Inc (NYSE:JXN) over the past three months, with no change in sentiment. The average 12-month price target for JXN has been raised to $43.75, up from $36.00, with a high estimate of $55.00 and a low of $35.00. Analysts from Goldman Sachs and Morgan Stanley have raised their price targets, while Jefferies has announced a hold rating with a target of $55.00. Despite a revenue decline of -12.1% as of September 30, 2023, JXN has a high net margin of 105.66% and an ROE of 32.37%, indicating strong profitability and financial performance.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 3:00 pm

BPMC

Blueprint Medicines (NASDAQ:BPMC) has been evaluated by 8 analysts over the last three months, with ratings ranging from bullish to bearish. The average 12-month price target for BPMC is now $84.62, up from $72.83, with a high estimate of $115.00 and a low of $58.00. Analysts from firms like Stifel, Raymond James, and Wells Fargo have raised their price targets, while others maintain or announce their ratings. Blueprint Medicines is a biopharmaceutical company with a focus on kinase-driven diseases. Despite the positive analyst sentiment, the company has seen a revenue decline of -14.26% and struggles with profitability and debt management.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 3:00 pm

ARES

Jefferies analyst Gerald O'Hara has downgraded Ares Management (NYSE:ARES) from Buy to Hold and set a price target of $122.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 2:59 pm

RPD

Citigroup analyst Fatima Boolani has upgraded Rapid7 (NASDAQ:RPD) from Neutral to Buy and increased the price target from $54 to $65.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 2:54 pm

SRPT

Wedbush analyst Andreas Argyrides has reiterated an Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) and maintained a price target of $224.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 2:52 pm

UNP

JP Morgan analyst Brian Ossenbeck has maintained a Neutral rating on Union Pacific (NYSE:UNP) but has lowered the price target from $240 to $239.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 2:44 pm

NSC

JP Morgan analyst Brian Ossenbeck has maintained an Overweight rating on Norfolk Southern (NYSE:NSC) but has reduced the price target from $238 to $237.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 2:43 pm